DEFLAZACORT OR PREDNISONE TREATMENT FOR DUCHENNE MUSCULAR DYSTROPHY (DMD): REAL-WORLD OUTCOMES AT CINCINNATI CHILDREN’S HOSPITAL MEDICAL CENTER (CCHMC) View the Full PDF
Consistency of 48-week changes in North Star Ambulatory Assessment (NSAA) between Duchenne muscular dystrophy (DMD) natural history data and clinical trial placebo arms, after adjustment for prognostic factors View the Full PDF
ESTIMATING CLINICALLY MEANINGFUL CHANGE THRESHOLDS IN THE NORTH STAR AMBULATORY ASSESSMENT (NSAA) AND FOUR-STAIR CLIMB (4SC) IN DUCHENNE MUSCULAR DYSTROPHY (DMD) View the Full PDF
Changes in Four-Stair Climb (4SC) over Two Years in Duchenne Muscular Dystrophy (DMD): Consistency across Data Sources and Prognostic Factors View the Full PDF
Published December 5, 2018 The collaborative Trajectory Analysis Project (cTAP), a multi-stakeholder, non-competitive global coalition in Duchenne muscular dystrophy, today announced that Analysis Group Managing Principal James Signorovitch, cTAP’s partner, has been selected as recipient of ISPOR’s “Best General Research Podium Presentation” award at ISPOR Europe 2018, which recently took place in Barcelona, Spain. Dr. Signorovitch’s research presentation titled Ambulatory Function in Duchenne Muscular Dystrophy (DMD): The Characteristic Trajectory and Variation Across Individuals, will be...
November 2018 Susan J. Ward presented at Action Duchenne 2018. The presentation is entitled “Collaborative Learning from Patient Data.” View the Full PDF